Consensus Approach to a Treat-to-target Strategy in Juvenile Idiopathic Arthritis Care: Report From the 2020 PR-COIN Consensus Conference

REFERENCES

1. 1.↵
   1. Petty RE,
   2. Southwood TR,
   3. Manners P, et al

   . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.

   OpenUrlFREE Full Text
2. 2.↵
   1. Manners PJ,
   2. Bower C

   . Worldwide prevalence of juvenile arthritis – why does it vary so much? J Rheumatol 2002;29:1520-30.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Thierry S,
   2. Fautrel B,
   3. Lemelle I,
   4. Guillemin F

   . Prevalence and incidence of juvenile idiopathic arthritis: a systemic review. Joint Bone Spine 2014;81:112-7.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Berthold E,
   2. Månsson B,
   3. Kahn R

   . Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther 2019;21:218.

   OpenUrlPubMed
5. 5.↵
   1. Oen K,
   2. Guzman J,
   3. Dufault B, et al; Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) investigators

   . Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis. Arthritis Care Res 2018;70:134-44.

   OpenUrl
6. 6.↵
   1. Guzman J,
   2. Oen K,
   3. Tucker LB, et al; ReACCh-Out investigators

   . The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854-60.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Consolaro A,
   2. Giancane G,
   3. Alongi A, et al; Paediatric Rheumatology International Trials Organisation

   . Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health 2019;3:255-63.

   OpenUrl
8. 8.↵
   1. Minden K,
   2. Niewerth M,
   3. Listing J, et al

   . Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Chhabra A,
   2. Robinson C,
   3. Houghton K, et al

   . Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. Rheumatology 2020;59:3727-30.

   OpenUrl
10. 10.↵
    1. Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)

    . [Internet. Accessed February 11, 2022.] Available from: https://www.pr-coin.org
11. 11.↵
    1. Kilo CM

    . A framework for collaborative improvement: lessons from the Institute for Healthcare Improvement’s breakthrough series. Qual Manag Health Care 1998,6:1-13.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Harris JG,
    2. Bingham CA,
    3. Morgan EM

    . Improving care delivery and outcomes in pediatric rheumatic diseases. Curr Opin Rheumatol 2016;28:110-6.

    OpenUrl
13. 13.↵
    1. Smitherman EA,
    2. Consolaro A,
    3. Morgan EM

    . Treat to target in juvenile idiopathic arthritis: challenges and opportunities. Curr Treatment Opt Rheumatol 2018;4:29-43.

    OpenUrl
14. 14.↵
    1. Ramiro S,
    2. Landewé RB,
    3. Van Der Heijde D, et al

    . Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann Rheum Dis 2020;79:453-9.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Stoffer MA,
    2. Schoels MM,
    3. Smolen JS, et al

    . Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016;75:16-22.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Ravelli A,
    2. Consolaro A,
    3. Horneff G, et al

    . Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77:819-28.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Buckley L,
    2. Ware E,
    3. Kreher G,
    4. Wiater L,
    5. Mehta J,
    6. Burnham J

    . Improving outcomes using a treat to target approach and clinical decision support in polyarticular juvenile idiopathic arthritis [abstract]. Arthritis Rheumatol 2017;69 (Suppl 10).
18. 18.↵
    1. Brinkman WB,
    2. Lipstein EA,
    3. Taylor J, et al

    . Design and implementation of a decision aid for juvenile idiopathic arthritis medication choices. Pediatr Rheumatol Online J 2017;15:48.

    OpenUrl
19. 19.↵
    1. Harris J,
    2. Morgan E,
    3. Taylor J, et al

    . Implementing treat to target approach in the care of juvenile idiopathic arthritis across a network of pediatric rheumatology centers [abstract]. Arthritis Rheumatol 2020;72 (Suppl 4).
20. 20.↵
    1. Zoom

    . [Internet. Accessed October 22-23, 2020.] Available from: https://zoom.us
21. 21.↵
    1. Schoemaker CG,
    2. Wit MPT

    . Treat-to-target from the patient perspective is bowling for a perfect strike. Arthritis Rheumatol 2021;73:9-11.

    OpenUrl
22. 22.↵
    1. Swart JF,
    2. van Dijkhuizen EHP,
    3. Wulffraat NM,
    4. de Roock S

    . Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Ann Rheum Dis 2018;77:336-42.

    OpenUrlAbstract/FREE Full Text
23. 23.
    1. Consolaro A,
    2. Giancane G,
    3. Schiappapietra B, et al

    . Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatology 2016;14:23.

    OpenUrl
24. 24.
    1. Schoemaker CG,
    2. Swart JF,
    3. Wulffraat NM

    . Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals? Pediatr Rheumatol 2020;18:34.

    OpenUrl
25. 25.
    1. Buckley L,
    2. Ware E,
    3. Kreher G,
    4. Wiater L,
    5. Mehta J,
    6. Burnham JM

    . Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis. J Rheumatol 2020;47:273-81.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Morgan EM,
    2. Munro JE,
    3. Horonjeff J, et al

    . Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA workshop. J Rheumatol 2019;46:1006-13.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Delbecq A,
    2. Ven A,
    3. Gustafson D

    . Group techniques for program planning: a guide to nominal group and Delphi processes. Glenview, III: Scott, Foresman; 1986.
28. 28.↵
    1. Poll everywhere

    . [Internet. Accessed February 11, 2022.] Available from: https://www.polleverywhere.com
29. 29.↵
    1. Lipstein EA,
    2. Brinkman WB,
    3. Britto MT

    . What is known about parents’ treatment decisions? A narrative review of pediatric decision making. Med Decis Mak 2012;32:246-58.

    OpenUrl
30. 30.↵
    1. El Miedany Y,
    2. El Gaafary M,
    3. Lotfy H, et al; PRINTO Egypt

    . Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking. Clin Rheumatol 2019;38:3217-25.

    OpenUrl
31. 31.↵
    1. Chang JC,
    2. Xiao R,
    3. Burnham JM,
    4. Weiss PF

    . Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention. Pediatr Rheumatol Online J 2020;18:88.

    OpenUrl
32. 32.↵
    1. Toupin-April K,
    2. Décary S,
    3. de Wit M, et al

    . Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: results from a multi-stepped consensus-building approach. Semin Arthritis Rheum 2021; 51:593-600.

    OpenUrl